<DOC>
	<DOCNO>NCT00175565</DOCNO>
	<brief_summary>Systemic inflammation present chronic obstructive pulmonary disease ( COPD ) , link cardiovascular morbidity mortality . We determine effect oral inhaled corticosteroid serum marker inflammation patient stable COPD .</brief_summary>
	<brief_title>Inhaled Steroid Reduces Systemic Inflammation COPD</brief_title>
	<detailed_description>We recruit patient age 45 80 year , stable symptom COPD previous 3 month study entry . All patient force expiratory volume one second ( FEV1 ) bronchodilation 400 mcg salbutamol 25 90 % predict , change le 20 % predict FEV1 , 30 minute follow bronchodilation , FEV1/forced vital capacity ( FVC ) less 75 % . Patients also history least 10 pack-years smoking prolonged exposure ( &gt; 10 year ) noxious gas ( e.g . diesel fume ) . At first visit , patient , take inhaled corticosteroid , ask immediately discontinue use medication . They allow take anti-COPD medication . None patient take theophylline time study entry new medication commence first second visit . The patient return 4 week later second visit , point , randomize one three arm trial : placebo capsule placebo puffer , fluticasone ( 500 mcg twice daily ) placebo capsule , prednisone ( 30 mg daily ) placebo puffer . The trial period last 2 week . Patients assign fluticasone ( 500 mcg twice daily ) 8 week un-blinded fashion , follow additional 8 week fluticasone 1000 mcg twice daily . At visit , measure participant ' serum C-reactive protein ( CRP ) level use nephelometry accordance recommendation Center Disease Control American Heart Association . We also measure serum concentration interleukin-6 ( IL-6 ) monocyte chemoattractant protein-1 ( MCP-1 ) . IL-6 measured powerful signal cytokine CRP expression liver know , independent risk factor cardiovascular events.22,23 MCP-1 measured may play central role pathogenesis COPD24 know risk factor atherosclerosis , myocardial infarction cardiac death . All sample analyze duplicate . For analytic purpose , continuous variable normally distribute ( include CRP value ) log-transformed achieve normality . We use pair t-test compare log-transformed CRP value visit 2 ( i.e . time randomization ) visit 3 ( end randomize trial phase ) within treatment group . Similarly , use visit 2 referent CRP value , use pair t-tests compare log-transformed CRP value across visit . To assess whether gradient log-transformed CRP value placebo , fluticasone prednisone group , also use Mantel-Haenszel test trend . We reason priori oral prednisone , potent systemic corticosteroid inhale fluticasone , would large effect CRP , follow fluticasone . Linear regression use examine association change interleukin-6 log-transformed CRP value visit 1 2 visit 2 3 . Continuous variable express meanSD , unless otherwise specify .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>stable symptom COPD previous 3 month study entry ; force expiratory volume one second ( FEV1 ) bronchodilation 400 mcg salbutamol 25 90 % predict , change le 20 % predict FEV1 , 30 minute follow bronchodilation , FEV1/forced vital capacity ( FVC ) less 75 % ; history least 10 packyears smoke prolonged exposure ( &gt; 10 year ) noxious gas ( e.g . diesel fume ) . active malignancy ; unable follow instruction ; patient take antiinflammatory medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>inflammation</keyword>
	<keyword>trial</keyword>
	<keyword>fluticasone</keyword>
</DOC>